The global hemostasis products market is projected to grow from USD 1.94 billion in 2025 to USD 3.28 billion by 2035, at a CAGR of 5.41%. Growth is driven by increasing surgical procedures, trauma cases, and demand for advanced bleeding control technologies. However, high product costs and low reimbursement in developing nations pose challenges. Topical hemostats and sponge/pad forms dominate the market, while flowable hemostats and matrix/gel forms show fastest growth. North America leads with 41.62% market share, while Asia-Pacific is the fastest-growing region.

The global Pulmonary Artery Catheter Market is valued at USD 1.23 billion in 2025 and is projected to reach USD 1.97 billion by 2035, growing at a CAGR of 4.87%. Growth is driven by increasing critical care procedures, rising cardiovascular disease prevalence, expanding ICU capacities, and demand for precise hemodynamic monitoring. The U.S. market is expected to grow from USD 0.38 billion to USD 0.58 billion during the same period.

Becton Dickinson reported Q1 2026 adjusted earnings of $2.91 per share, beating consensus of $2.81, with sales of $5.25 billion slightly above the $5.15 billion consensus. However, the company significantly lowered its fiscal 2026 adjusted earnings guidance to $12.35-$12.65 per share from $14.75-$15.05, citing transition year headwinds in China, vaccines, and Alaris. Multiple analysts cut price targets, with RBC reducing its forecast from $210 to $172, Wells Fargo from $184 to $157, and Piper Sandler from $205 to $170. BDX shares fell 17.44% to $171.23.

Becton Dickinson reported Q1 2026 adjusted earnings of $2.91 per share, beating consensus of $2.81, with sales of $5.25 billion slightly above expectations. However, the company significantly lowered its fiscal 2026 adjusted earnings guidance from $14.75-$15.05 per share to $12.35-$12.65 per share, well below the consensus of $14.72. The guidance cut follows the company's spinoff and combination of its Biosciences and Diagnostic Solutions business with Waters Corporation.

The article highlights three Dividend Kings—stocks with 50+ consecutive years of dividend increases—as attractive options for 2026. Becton, Dickinson & Co. (BDX) is a medical supply leader with strong earnings growth. H2O America (HTO) is a water utility benefiting from population growth in high-demand regions. Stepan Company (SCL) manufactures specialty chemicals but recently missed earnings estimates.

A comprehensive market research report on over-the-counter and direct-to-consumer infectious disease diagnostics forecasts significant growth through 2029, driven by rapid testing technologies, privacy concerns, and digital accessibility. The report analyzes market trends across 15 countries, covering respiratory, STD, UTI, and other infectious disease testing channels, with profiles of 70+ diagnostic companies.

The global advanced wound closure market is projected to grow from USD 18.47 billion in 2025 to USD 32.54 billion by 2035, at a CAGR of 6.9%. Growth is driven by increasing surgical procedures, rising chronic wounds and diabetes cases, and technological innovations in surgical sealants, hemostats, and tissue adhesives. North America leads the market while Asia Pacific shows the highest growth potential.

Becton Dickinson's Board of Directors declared a quarterly dividend of $1.05 per share (annual rate of $4.20) payable March 31, 2026. The company has completed $250 million in stock repurchases in fiscal 2026 and authorized an additional 10 million shares for repurchase under its capital allocation program.

The global anatomic pathology market is projected to grow from $93.03 billion in 2024 to $224.44 billion by 2033 at a CAGR of 10.28%, driven by rising cancer burden, aging populations, and AI-powered digital pathology adoption. North America leads with over 41% market share, supported by advanced healthcare infrastructure and precision oncology investments. Disease diagnostics account for 74.42% of revenue, with cancer diagnostics representing 60% of biopsy applications globally.

A comprehensive market analysis report on atherectomy devices covering 39 countries with forecasts through 2036. The market is driven by the shift toward minimally-invasive techniques for treating coronary and peripheral artery diseases, replacing traditional bypass surgery. The report provides detailed market segmentation, intervention volumes, competitive dynamics, and regulatory insights across developed markets.

Becton, Dickinson and Company received FDA 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System, with market launch expected in early 2026. The advanced system features high and low vacuum strengths, 360-degree sampling ability, and multiple probe options. However, analysts expect slightly lower earnings and revenue compared to the prior year quarter, and the stock is considered overvalued despite a consensus Buy rating.

The global catheters market is projected to grow from USD 29.17 billion in 2025 to USD 55.58 billion by 2033, with a CAGR of 8.41%. Growth is driven by increasing cardiovascular and urological procedures, aging populations, and technological advancements. However, catheter-associated infections and antibiotic resistance pose challenges. North America dominates with 38.05% market share, while Asia Pacific is the fastest-growing region at 9.23% CAGR.